Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Series BB venture round brings in $25mm for Aptus Endosystems

Executive Summary

Aptus Endosystems Inc. (devices for endovascular aneurysm repair) has raised $25mm through its Series BB venture round. New backer Synergy Life Science Partners led (and gains a seat on the company’s board) and was joined by current shareholders US Venture Partners and Longitude Capital Management. Aptus will use the money to increase commercialization of its HeliFX aortic securement system in the US and Europe, where the product is already approved, and continue developing the device for unmet needs in aortic aneurysm treatment. The company is planning a US clinical trial to support PMA filing for its Fortevo abdominal aortic aneurysm endograft system; funds will also be used to broaden marketing across Europe, where it has the CE Mark.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register